LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

Home・Elenco Azioni・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Aperta

SettoreSettore sanitario

11.36 1.34

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.8

Massimo

11.4

Metriche Chiave
By Trading Economics
Entrata	227M
Vendite	139M
P/E Media del settore	4.522 50.102
Margine di Profitto	163.843
Dipendenti	1,796
EBITDA	1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+43.34% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2.1B
Apertura precedente	10.02
Chiusura precedente	11.36

Notizie sul Sentiment di mercato

By Acuity

10%

90%

5 / 344 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 mag 2026, 22:47 UTC

Utili

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mag 2026, 20:45 UTC

Utili

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mag 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mag 2026, 23:31 UTC

Discorsi di Mercato

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mag 2026, 23:17 UTC

Discorsi di Mercato

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mag 2026, 23:02 UTC

Discorsi di Mercato

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mag 2026, 22:37 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mag 2026, 21:12 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mag 2026, 21:00 UTC

Utili

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mag 2026, 20:57 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:55 UTC

Utili

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

28 mag 2026, 20:48 UTC

Azioni calde

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mag 2026, 20:34 UTC

Utili

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mag 2026, 20:31 UTC

Utili

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mag 2026, 20:28 UTC

Utili

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mag 2026, 20:26 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Membership Fees $1.37B

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Net Sales $69.15B

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Same-Store Sales Up 9.8% >COST

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

43.34% in crescita

Previsioni per 12 mesi

Media 16.8 USD 43.34%

Alto 20 USD

Basso 13.6 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 2 che hanno fornito valutazioni azionarie a Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

5 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.